Literature DB >> 6939513

Sulphate conjugation of biologically active monoamines and their metabolites by human platelet phenolsulphotransferase.

G Rein, V Glover, M Sandler.   

Abstract

The substrate specificity of phenosulphotransferase in human platelets has been studied using a wide range of biogenic amines and their metabolites. Substantially differing activities were observed at 30 mumol/l; the enzyme was more active towards the catecholamines and their alcoholic metabolites than the corresponding acids (with the exception of 3,4-dihydroxyphenylacetic acid which did not appear to be a substrate) and the relative order was not changed by dialysis to remove possible low molecular mass inhibitors. However, most of the V values were similar to each other, reflecting a large variation if Km values, ranging from 0.3 mumol/l for 3-methoxytyramine to 3700 mumol/l for 4-hydroxy-3-methoxymandelic acid. All substrates showed substrate inhibition. Dopamine, noradrenaline and adrenaline all had a high affinity for the enzyme, with Km values of 3.0, 5.0 and 2.7 mumol/l respectively. These values are considerably lower than those for monoamine oxidase and the relative importance of oxidation and sulphoconjugation of these amines in vivo may be concentration dependent. Human platelet phenolsulphotransferase appears different from the rat enzyme, but similar to that described by others in human brain. The platelet should be a useful source of enzyme for clinical studies.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6939513     DOI: 10.1016/0009-8981(81)90192-3

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  9 in total

1.  Red wine contains a potent inhibitor of phenolsulphotransferase.

Authors:  J T Littlewood; V Glover; M Sandler
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

2.  Sulphate conjugation of beta 2-adrenoceptor stimulating drugs by platelet and placental phenol sulphotransferase.

Authors:  R J Sodha; H Schneider
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

3.  Low platelet monoamine oxidase activity in headache: no correlation with phenolsulphotransferase, succinate dehydrogenase, platelet preparation method or smoking.

Authors:  J Littlewood; V Glover; M Sandler; R Peatfield; R Petty; F Clifford Rose
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-04       Impact factor: 10.154

4.  Platelet phenolsulphotransferase activity in Parkinson's disease.

Authors:  V Glover; A J Lees; C Ward; G M Stern; M Sandler
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

5.  alpha-Methyldopa, alpha-methyldopamine an alpha-methylnoradrenaline: substrates for the thermolabile form of human platelet phenol sulphotransferase.

Authors:  G Mwaluko; R Weinshilboum
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

6.  A polyhydric phenol sulfokinase and chronic liver injury.

Authors:  T Ozeki; N Inoue; M Kan; S Yamagata; K Wakui; K Ouchi
Journal:  Gastroenterol Jpn       Date:  1982

7.  Human platelet phenolsulphotransferase M and P: substrate specificities and correlation with in vivo sulphoconjugation of paracetamol and salicylamide.

Authors:  S M Bonham Carter; G Rein; V Glover; M Sandler; J Caldwell
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

8.  Thermolabile and thermostable human platelet phenol sulfotransferase. Substrate specificity and physical separation.

Authors:  C Reiter; G Mwaluko; J Dunnette; J Van Loon; R Weinshilboum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

9.  Interindividual variability of phenol- and catechol-sulphotransferases in platelets from adults and newborns.

Authors:  G M Pacifici; G Marchi
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.